Autonomix Medical

Autonomix Medical Autonomix (Nasdaq: AMIX) is focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.

06/10/2026

As part of a new CEO Corner segment, Autonomix CEO Brad Hauser highlights the Company’s growing scientific and clinical recognition as its differentiated nerve-sensing and transvascular denervation platform gains traction across leading global medical conferences. Watch here: https://bit.ly/40qP3vL

06/10/2026

Autonomix today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. Watch here: https://bit.ly/40qP3vL

06/04/2026

In the latest Virtual Investor “What This Means” segment, Dr. Toufic Kachaamy discusses the clinical significance of Autonomix’s data recently presented at the Society of Surgical Oncology Annual Meeting, highlighting the importance of the work being selected for a podium presentation and its relevance to the surgical oncology community. Watch here: https://bit.ly/42Vr0q2

06/04/2026

In a new Virtual Investor “What This Means” segment, Dr. Toufic Kachaamy discusses what differentiates Autonomix’s approach to treating visceral cancer pain, the significance of its pancreatic cancer feasibility data, and the broader potential of its peripheral nervous system platform. Watch here: https://bit.ly/42Vr0q2

05/19/2026

Brad Hauser, Chief Executive Officer of Autonomix Medical, comments on the issuance of a new U.S. patent that further strengthens the Company’s intellectual property foundation for next-generation neuromodulation technologies: https://bit.ly/4dCdoW0 $AMIX

05/19/2026

Autonomix's recently issued patent provides intellectual property protection for technology that unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall. Read more about Autonomix's growing global patent portfolio: https://bit.ly/4dCdoW0

05/19/2026

Autonomix today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131 (the “131 patent”), titled “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall.” Read more: https://bit.ly/4dCdoW0

05/18/2026

“These abstract acceptances at EuroPCR underscore the expanding interest in precision-guided, transvascular approaches to peripheral nerve targeting,” said Brad Hauser, Chief Executive Officer of Autonomix. Read more about the upcoming presentation: https://bit.ly/3RLO7kI

05/18/2026

Autonomix today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France. Read more: https://bit.ly/3RLO7kI

05/12/2026

May is National Cancer Research Month and a time to recognize that the treatments we take for granted today were once just a hypothesis.

At Autonomix, we are building technology we believe could matter enormously for pancreatic cancer patients. Our catheter-based technology is designed to sense, map, and ablate the nerves responsible for severe pain - a symptom that affects the majority of this patient population.

We recognize everyone working on the hardest problems in oncology - and thank you for not giving up.

Address

The Woodlands, TX
77380

Website

Alerts

Be the first to know and let us send you an email when Autonomix Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category